Employees: 5,081
Size Cofoe Medical Technology (1187.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $836M, the 624th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$29.00 on 18 Nov 2026.
Performance Over six months the shares fell 10.6%, against -13.2% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 40.2% over the last twelve months (peer median +6.2%); the operating margin is 9.9% (peer median 10.2%).
Valuation It trades at 13.1× forward earnings against a peer median of 22.4× (5th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.5 points above its cost of capital (8.1% WACC).
Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.75B | HK$3.66B | HK$3.23B | HK$3.14B | HK$3.45B |
| Revenue growth | — | +13% | +3% | -9% | — |
| Gross profit | HK$2.69B | HK$1.79B | HK$1.54B | HK$1.24B | HK$1.27B |
| EBITDA | n/a | HK$573M | HK$532M | HK$405M | HK$437M |
| Net income | HK$472M | HK$403M | HK$338M | HK$281M | HK$351M |
| Free cash flow | HK$297M | HK$604M | HK$604M | HK$70.9M | -HK$555M |
| Capital expenditure | HK$163M | HK$193M | HK$131M | HK$412M | HK$744M |
| Total debt | HK$1.56B | HK$1.02B | HK$1.07B | HK$820M | HK$648M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1187.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | -8.0% | 4th highest of 21 |
| 6-month return | -10.6% | -13.2% | 9th highest of 21 |
| Distance from 52-week high | -29.3% | -41.9% | 8th highest of 21 |
| Revenue growth (TTM) | +40.2% | +6.2% | 3rd highest of 21 |
| Operating margin | 9.9% | 10.2% | 10th lowest of 21 |
| Forward P/E | 13.1× | 22.4× | 5th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -6.4% | 11.1% | 4th least demanding of 14 |
| Growth delivered (Del g) | +6.6% | +12.4% | 5th lowest of 14 |
| Hurdle (Req g minus delivered) | -13.0 pp | -1.4 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +4.5 pp | -0.0 pp | 6th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | n/a | n/a | n/a |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 25.8× | 2.7% | +20.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 56.2× | n/a | n/a |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |